Nov. 24 at 5:00 PM
$WRD 🏗️ The risk-reward on valuation is crazy to me, Mainz Biomed trades at a P/S around ~5–6x on <
$1M revenue while multi-billion peers get 7–15x on
$1–3B, but the science here (CRC and pancreatic sensitivities in the 90%+ range) is absolutely competitive, I’m basically paying a ~
$5M tag for a platform that could justify a 20–40M, 80M or 120M cap on just
$10–30M revenue, which makes my
$14 target (+1,328.57% upside) feel like a rational bull case and not just a dream